{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:06:10Z","timestamp":1791446770528,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.amjcard.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T04:25:21Z","timestamp":1670214321000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-3185","authenticated-orcid":false,"given":"Riley J.","family":"Batchelor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Nan Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.11.001_bib0001","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0002","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00392-017-1137-7","article-title":"Epidemiology of heart failure in Germany: a retrospective database study","volume":"106","author":"St\u00f6rk","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"suppl 3","key":"10.1016\/j.amjcard.2022.11.001_bib0003","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/00005344-198700003-00021","article-title":"Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study","volume":"9","author":"Chalmers","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees","volume":"90","author":"Lachat","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0009","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL Randomised Intervention Trial In-Congestive Heart Failure (MERIT-HF)","volume":"353","author":"Hjalmarson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Lachat","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (Copernicus) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0013","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin Inhibition versus enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0016","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0017","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","article-title":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018","volume":"27","author":"Atherton","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0018","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0019","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0021","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/eurheartj\/eht290","article-title":"An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0022","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0023","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0025","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0","article-title":"Chapter 7: Selecting Studies and Collecting Data","year":"2011"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0026","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. version 5.1.0","article-title":"Chapter 8: Assessing risk of bias in included studies","year":"2011"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0027","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0028","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/0735-1097(92)90529-V","article-title":"Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial","volume":"19","author":"Fonarow","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0029","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/j.1552-4604.1995.tb04107.x","article-title":"Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group","volume":"35","author":"Beller","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00192366","article-title":"Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure","volume":"49","author":"Widimsk\u00fd","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0735-1097(95)80020-H","article-title":"Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure","volume":"26","author":"Dickstein","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0032","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0033","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0034","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","article-title":"Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors","volume":"139","author":"Granger","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0035","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0036","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0037","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0038","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","article-title":"Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group","volume":"3","author":"Cohn","year":"1997","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0039","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1054\/jcaf.2003.42","article-title":"Failure of benefit and early hazard of bucindolol for class IV heart failure","volume":"9","author":"Anderson","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0041","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","article-title":"Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study","volume":"7","author":"Edes","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0042","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0043","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","article-title":"Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asakura","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0044","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0046","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0047","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":"Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial","volume":"289","author":"Young","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0048","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0049","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ahj.2010.03.008","article-title":"A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial","volume":"159","author":"Boriani","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0050","unstructured":"McMurray J, Gong J, Rouleau J, Solomon S, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M. Efficacy and safety of sacubitril\/valsartan in patients in NYHA functional class IV: an analysis of PARADIGM HF 2018;134:A20000."},{"key":"10.1016\/j.amjcard.2022.11.001_bib0051","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0052","first-page":"l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0053","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0054","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.healun.2018.07.022","article-title":"The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation Report-2018; focus theme: multiorgan transplantation","volume":"37","author":"Khush","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: mechanisms: part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0056","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2011.10.001","article-title":"Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF","volume":"163","author":"Wilcox","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0057","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD investigators","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0058","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.amjcard.2010.11.033","article-title":"Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy","volume":"107","author":"Hoshikawa","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0059","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0735-1097(97)00012-0","article-title":"Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand heart failure research collaborative group","volume":"29","author":"Doughty","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0060","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.11.001_bib0061","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:44:44Z","timestamp":1757573084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922011857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":61,"alternative-id":["S0002914922011857"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.11.001","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}